| Ticker Details |
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
|
| IPO Date: |
September 1, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.12B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 2.66%
|
| Avg Daily Range (30 D): |
$0.26 | 1.76%
|
| Avg Daily Range (90 D): |
$0.22 | 1.45%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.72M |
| Avg Daily Volume (30 D): |
.98M |
| Avg Daily Volume (90 D): |
.88M |
| Trade Size |
| Avg Trade Size (Sh.): |
165 |
| Avg Trade Size (Sh.) (30 D): |
65 |
| Avg Trade Size (Sh.) (90 D): |
68 |
| Institutional Trades |
| Total Institutional Trades: |
2,648 |
| Avg Institutional Trade: |
$1.3M |
| Avg Institutional Trade (30 D): |
$1.82M |
| Avg Institutional Trade (90 D): |
$1.72M |
| Avg Institutional Trade Volume: |
.11M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.37M |
| Avg Closing Trade (30 D): |
$2.25M |
| Avg Closing Trade (90 D): |
$1.92M |
| Avg Closing Volume: |
129.54K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$2.14
|
$1.6
|
$2.14
|
|
Diluted EPS
|
$2.07
|
$1.53
|
$2.07
|
|
Revenue
|
$283.06M
|
$77.11M
|
$283.06M
|
|
Gross Profit
|
$250.39M
|
$68.32M
|
$250.39M
|
|
Net Income / Loss
|
$287.2M
|
$210.79M
|
$287.2M
|
|
Operating Income / Loss
|
$104.91M
|
$33.24M
|
$104.91M
|
|
Cost of Revenue
|
$32.67M
|
$8.8M
|
$32.67M
|
|
Net Cash Flow
|
$-3.22M
|
$7.02M
|
$-3.22M
|
|
PE Ratio
|
7.62
|
|
|
|
|
|
